Company profile: Revelation Biosciences
1.1 - Company Overview
Company description
- Provider of immunologic therapeutics and diagnostics, including Gemini, a proprietary PHAD formulation for systemic administration for prevention of post-surgical infection, acute kidney injury, and chronic kidney disease; GEM-AKI and GEM-CKD therapies that redirect the innate immune response; and GEM-SSI for prevention or treatment of healthcare-associated bacterial infections (post-surgical/post-burn, UTIs, sepsis, antibiotic-resistant).
Products and services
- GEM-AKI: An immunologic potential therapy that redirects the innate immune response from a pro-inflammatory to anti-inflammatory state to treat acute kidney injury (AKI)
- GEM-CKD: An immunologic potential therapy that redirects the innate immune response from pro-inflammatory to anti-inflammatory states for treating chronic kidney disease (CKD)
- Gemini: A proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) for systemic administration engineered for prevention of post-surgical infection and treatment of acute kidney injury and chronic kidney disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Revelation Biosciences
Micropharma
HQ: Canada
Website
- Description: Provider of biotherapeutics, diagnostics, and devices for metabolic diseases, discovering and developing bacteria-based biotherapeutics and novel probiotic and enzymatic solutions through a unique approach from basic research to product development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micropharma company profile →
Stat-Sure Diagnostics
HQ: United States
Website
- Description: Provider of diagnostic testing specializing in HIV.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stat-Sure Diagnostics company profile →
ANA Therapeutics
HQ: United States
Website
- Description: Provider of biotech therapeutics developing a novel coronavirus vaccine and niclosamide-based treatments to enable medical practitioners to treat patients with COVID-19; founded in 2020 and headquartered in Foster City, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ANA Therapeutics company profile →
Ashvattha Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision nanomedicines and PET imaging agents, developing D-4517.2 for wet AMD and DME, OP-801 targeting CNS macrophages/microglia as a biomarker of neuroinflammation, OP-101 to modulate inflammatory cell activity in severe COVID-19 and other inflammatory diseases, and CSF1R Dendranib, a CSF1R tyrosine kinase inhibitor for multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ashvattha Therapeutics company profile →
Virion Serion
HQ: Germany
Website
- Description: Provider of in-vitro diagnostic products for infectious disease detection—viral, bacterial, fungal, and parasitic—including classic tests recommended for quantified antibodies and products that allow simultaneous antibody detection against multiple antigens using flow cytometry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Virion Serion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Revelation Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Revelation Biosciences
2.2 - Growth funds investing in similar companies to Revelation Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Revelation Biosciences
4.2 - Public trading comparable groups for Revelation Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →